These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
139 related articles for article (PubMed ID: 10456463)
1. A bispecific antifibrin-antiplatelet urokinase conjugate (BAAUC) induces enhanced clot lysis and inhibits platelet aggregation. Ruef J; Nordt TK; Peter K; Runge MS; Kübler W; Bode C Thromb Haemost; 1999 Jul; 82(1):109-14. PubMed ID: 10456463 [TBL] [Abstract][Full Text] [Related]
2. Platelet-targeted fibrinolysis enhances clot lysis and inhibits platelet aggregation. Bode C; Meinhardt G; Runge MS; Freitag M; Nordt T; Arens M; Newell JB; Kübler W; Haber E Circulation; 1991 Aug; 84(2):805-13. PubMed ID: 1860223 [TBL] [Abstract][Full Text] [Related]
3. Enhancement of clot lysis in vitro and in vivo with a bispecific monoclonal antibody directed against human fibrin and against urokinase-type plasminogen activator. Kurokawa T; Iwasa S; Kakinuma A; Stassen JM; Lijnen HR; Collen D Thromb Haemost; 1991 Dec; 66(6):684-93. PubMed ID: 1796414 [TBL] [Abstract][Full Text] [Related]
4. Hybrid molecules: insights into plasminogen activator function. Runge MS; Bode C; Haber E; Quertermous T Mol Biol Med; 1991 Apr; 8(2):245-55. PubMed ID: 1806766 [TBL] [Abstract][Full Text] [Related]
5. Effect of chemical conjugation of recombinant single-chain urokinase-type plasminogen activator with monoclonal antiplatelet antibodies on platelet aggregation and on plasma clot lysis in vitro and in vivo. Dewerchin M; Lijnen HR; Stassen JM; De Cock F; Quertermous T; Ginsberg MH; Plow EF; Collen D Blood; 1991 Aug; 78(4):1005-18. PubMed ID: 1831057 [TBL] [Abstract][Full Text] [Related]
6. In-vitro efficacy of different platelet glycoprotein IIb/IIIa antagonists and thrombolytics on platelet/fibrin-mediated clot dynamics in human whole blood using thrombelastography. Mousa SA Blood Coagul Fibrinolysis; 2007 Jan; 18(1):55-60. PubMed ID: 17179828 [TBL] [Abstract][Full Text] [Related]
7. Conjugation to antifibrin Fab' enhances fibrinolytic potency of single-chain urokinase plasminogen activator. Bode C; Runge MS; Schönermark S; Eberle T; Newell JB; Kübler W; Haber E Circulation; 1990 Jun; 81(6):1974-80. PubMed ID: 2111744 [TBL] [Abstract][Full Text] [Related]
8. Conjugation to an antifibrin monoclonal antibody enhances the fibrinolytic potency of tissue plasminogen activator in vitro. Runge MS; Bode C; Matsueda GR; Haber E Biochemistry; 1988 Feb; 27(4):1153-7. PubMed ID: 3130094 [TBL] [Abstract][Full Text] [Related]
9. Bispecific monoclonal antibodies produced by somatic cell fusion increase the potency of tissue plasminogen activator. Branscomb EE; Runge MS; Savard CE; Adams KM; Matsueda GR; Haber E Thromb Haemost; 1990 Oct; 64(2):260-6. PubMed ID: 2125375 [TBL] [Abstract][Full Text] [Related]
10. Hybridization to an anti-activated platelet monoclonal antibody enhances fibrinolytic potency on urokinase. Du L; Yu RR; Hua ZC; Zhu DX; Wu GX; Ruan CG Sci China B; 1993 Dec; 36(12):1483-9. PubMed ID: 8129836 [TBL] [Abstract][Full Text] [Related]
11. [Thrombus age as a determinant of lysis efficacy of in vitro produced platelet-fibrin thrombi]. Beythien C; Terres W; Gutensohn K; Meinertz T Z Kardiol; 1996 Sep; 85(9):661-7. PubMed ID: 8992809 [TBL] [Abstract][Full Text] [Related]
12. [Study on the in vitro and in vivo thrombolytic efficacy of bispecific antifibrin-antiurokinase monoclonal antibodies]. Yuan H; Lin H; Zhu X; Zhang Y; Zhang X Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 1998 Oct; 20(5):357-60. PubMed ID: 11717992 [TBL] [Abstract][Full Text] [Related]
13. Antiplatelet effects of urokinase and their clinical implications. Torr-Brown SR; Sobel BE Coron Artery Dis; 1996 Jan; 7(1):63-8. PubMed ID: 8773435 [TBL] [Abstract][Full Text] [Related]
15. Thrombolysis by a fibrin-specific antibody Fab'-urokinase conjugate. Bode C; Runge MS; Newell JB; Matsueda GR; Haber E J Mol Cell Cardiol; 1987 Apr; 19(4):335-41. PubMed ID: 3612817 [TBL] [Abstract][Full Text] [Related]
16. Conjugation and evaluation of 7E3 x P4B6, a chemically cross-linked bispecific F(ab')2 antibody which inhibits platelet aggregation and localizes tissue plasminogen activator to the platelet surface. Neblock DS; Chang CH; Mascelli MA; Fleek M; Stumpo L; Cullen MM; Daddona PE Bioconjug Chem; 1992; 3(2):126-31. PubMed ID: 1515466 [TBL] [Abstract][Full Text] [Related]
17. Characterization of an antibody-urokinase conjugate. A plasminogen activator targeted to fibrin. Bode C; Runge MS; Newell JB; Matsueda GR; Haber E J Biol Chem; 1987 Aug; 262(22):10819-23. PubMed ID: 3611093 [TBL] [Abstract][Full Text] [Related]
18. [Increased thrombolysis and decreased platelet aggregation with an anti-GPIIb/IIIa antibody urokinase hybrid molecule (7E3-UK)]. Bode C; Nordt T; Freitag M; Ruef J; Kaltenmeier M; Meinhardt G; Kübler W; Haber E Verh Dtsch Ges Inn Med; 1991; 97():1-2. PubMed ID: 1839701 [No Abstract] [Full Text] [Related]
19. Design and evaluation of a thrombin-activable plasminogen activator. Yang WP; Goldstein J; Procyk R; Matsueda GR; Shaw SY Biochemistry; 1994 Mar; 33(8):p606-12. PubMed ID: 8117652 [TBL] [Abstract][Full Text] [Related]
20. Functional properties of a novel mutant of staphylokinase with platelet-targeted fibrinolysis and antiplatelet aggregation activities. Chen H; Mo W; Zhang Y; Su H; Ma J; Yao R; Zhang S; Ge J; Song H Eur J Pharmacol; 2007 Jul; 566(1-3):137-44. PubMed ID: 17451675 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]